RENE.L Regulatory News (RENE)

RNS REACH

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron featured in BBC documentary "Andrew Marr: My Brain and Me"

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that its CTX cell therapy candidate has been featured in the BBC documentary, "Andrew Marr: My Brain and Me", which was screened for the first time last night on BBC2.

In the programme, the well-known broadcaster and political journalist Andrew Marr documents his mission to explore pioneering stroke treatments after suffering a life-threatening stroke four years ago, which has left him with reduced movement in his left arm, hand and leg.

Professor Keith Muir, the Principal Investigator of ReNeuron's Phase II clinical trial in stroke disability, is featured in the programme explaining the role of stem cells and how they are being used as a potential treatment for patients living with the chronic consequences of a stroke. The programme also follows the progress of a stroke patient who took part in ReNeuron's Phase II clinical trial.

On 5 December 2016, ReNeuron announced positive Phase II data from its clinical trial of its CTX cell therapy candidate for stroke disability. As a result of the positive data from the trial, the Company intends to apply to the US and European regulatory authorities to commence a randomised, placebo-controlled, pivotal clinical trial in patients who are living with disability post-stroke.

In addition to last night's national screening, the programme will air on BBC2 on 16 February 2017 at 11.15pm (England) and on 17 February 2017 at 12.05am (Wales).

The programme is also available to view on iPlayer at the following link: http://www.bbc.co.uk/iplayer/episode/b08flqbv/andrew-marr-my-brain-and-me 

ENQUIRIES:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.